autoimmune-995x60 autoimmune-995x60

FEATURED ARTICLES

AMO Pharma Addresses Rare Childhood Disease
AMO Pharma Addresses Rare Childhood Disease

“Rare diseases are bad enough, but the ones that affect children are even more heartbreaking,” says Mike Snape, CEO of AMO Pharma, a virtual biotech focused on rare disease. “The medical need in these areas is greater than ever. They also present challenges for drug developers, especially with clinical trials.”

  • NEWS ROUNDUP: Pharma Invests In Patients, More Trials Use FitBit Trackers
    NEWS ROUNDUP: Pharma Invests In Patients, More Trials Use FitBit Trackers

    Clinical Leader news roundup for the week of April 11, 2016, with articles on pharma’s investment in patients, FitBit activity trackers in clinical trials, new Hep C combination treatment tested in Malaysia and Thailand, prostate and pancreatic cancer trials, the need for clinical trial participants, and making the most of clinical trial data.

  • NEWS ROUNDUP: Santa Claus, The Easter Bunny, And Patient Centricity?
    NEWS ROUNDUP: Santa Claus, The Easter Bunny, And Patient Centricity?

    Clinical Leader news roundup for the week of April 4, 2016, with articles on Patient recruitment via Twitter, NIH sponsors trial of anti-HIV antibody, diversity in clinical trials, INC Research partners with CISCRP, the use of apps in clinical trials, and the myth of patient centricity.

  • Clinical BioStatistician/Programmer: A Day In The Life
    Clinical BioStatistician/Programmer: A Day In The Life

    Statisticians play an important role in many phases of the clinical trial process, beginning at the design stage and progressing through the final analysis. By Justin Sjogren, MS, Clinical BioStatistician/Programmer

More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors
    Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors

    Oncologists and their patients have had reason recently to be encouraged by the launch of immune checkpoint inhibitors (ICIs) for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer. These novel agents activate the human immune response against antigens expressed on tumor cells, and the science has generated excitement among physicians, patients, the media and researchers.

More White Papers & Case Studies

NEWS

More News